Skip to main content

Day: March 21, 2022

Sabina Gold & Silver Corp. Announces C$110 Million Bought Deal Financing

Not for distribution to U.S. news wire services or dissemination in the United States. VANCOUVER, British Columbia, March 21, 2022 (GLOBE NEWSWIRE) — Sabina Gold & Silver Corp. (SBB.T/SGSVF.OTCQX), (“Sabina” or the “Company”) has announced today that it has entered into an agreement with a syndicate of underwriters led by BMO Capital Markets (collectively, the “Underwriters”), under which the Underwriters have agreed to buy on a bought deal basis 71,000,000 common shares (the “Common Shares”) at a price of C$1.55 per Common Share for gross proceeds of approximately C$110 million (the “Offering”). The Company has granted the Underwriters an option, exercisable at the offering price for a period of 30 days following the closing of the Offering, to purchase up to an additional 15% of Common Shares issued to cover over-allotments,...

Continue reading

First Savings Financial Group, Inc. Completes $31.0 Million Subordinated Notes Offering

JEFFERSONVILLE, Ind., March 21, 2022 (GLOBE NEWSWIRE) — First Savings Financial Group, Inc. (the “Company”) (NASDAQ: FSFG), the holding company for First Savings Bank (the “Bank”), announced today the completion of a private placement offering of 4.50% Fixed-to-Floating Rate Subordinated Notes due 2032 (the “Notes”), in the aggregate principal amount of $31.0 million, to certain qualified institutional buyers and accredited institutional investors. The Company intends to use the net proceeds for general corporate purposes, including to fund organic growth, the future repayment of existing outstanding subordinated debt, and potential repurchases of shares of the Company’s outstanding common stock. The Notes are intended to qualify as Tier 2 capital for the Company for regulatory capital purposes, if applicable. The Notes mature...

Continue reading

Caribou Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

— Company plans to present initial ANTLER Phase 1 clinical data at a medical meeting in 2022 for CB-010, its lead allogeneic cell therapy candidate for patients with r/r B-NHL — — 2022 submission of IND application planned for CB-011, an allogeneic cell therapy candidate for patients with r/r multiple myeloma — — Leadership team expanded with appointment of Syed Rizvi, M.D., as chief medical officer — — Cash, cash equivalents, and marketable securities of $413.5 million as of December 31, 2021 support advancement of wholly owned pipeline of allogeneic CAR-T and CAR-NK cell therapies — BERKELEY, Calif., March 21, 2022 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported business highlights...

Continue reading

BTB REIT Announces $35 Million Bought Deal Equity Offering and Provides Capital Deployment & Operational Updates

Not for distribution to the United States Newswire Services or for Dissemination in the United States MONTRÉAL, March 21, 2022 (GLOBE NEWSWIRE) — BTB Real Estate Investment Trust (TSX: BTB.UN) (“BTB”, the “REIT” or the “Trust”) announces today that it has reached an agreement with a syndicate of underwriters led by National Bank Financial Inc. (the “Underwriters”) to issue to the public, subject to regulatory approval, on a bought deal basis 8,334,000 trust units (the “Units”) at a price of $4.20 per Unit for gross proceeds of approximately $35M. The REIT has granted the Underwriters an over-allotment option exercisable in whole or in part at any time up to 30 days after closing to purchase up to an additional 1,250,100 Units at the same offering price. $30M of the net proceeds from the sale of the Units will be used to repay amounts...

Continue reading

SeqLL Announces Formation of Scientific Advisory Board

BILLERICA, Mass., March 21, 2022 (GLOBE NEWSWIRE) — SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services for collaborative partnerships, today announced the formation of a Scientific Advisory Board (“SAB”) comprised of distinguished and world-renowned leaders of the scientific community. The SAB will discuss with management potential new development opportunities that leverage the Company’s unique True Single Molecule Sequencing (tSMS®) technology across the “omics” fields, as well as advise management with their existing collaborative, scientific, & development partnerships. Each leader has previously utilized the tSMS platform and will leverage their expertise to provide valuable insight to our company. “We are privileged to be working...

Continue reading

America First Multifamily Investors, L.P. Announces Sale of Vantage at Murfreesboro

OMAHA, Neb., March 21, 2022 (GLOBE NEWSWIRE) — America First Multifamily Investors, L.P. (NASDAQ: ATAX) (the “Partnership”) announced today that on March 17, 2022, Vantage at Murfreesboro, a 288-unit market rate multifamily property located in Murfreesboro, TN, was sold at the direction of the managing member of Vantage at Murfreesboro LLC (the “Property Owner”). The Partnership’s investment in the property was originated in September 2018 and the Partnership contributed equity totaling approximately $12.2 million during construction. As a result of the sale, the Partnership’s equity investment in the Property Owner was redeemed. At closing of the sale, the Partnership received net cash of approximately $29.4 million, inclusive of the return of its contributed equity. The Partnership will recognize the following in the first quarter...

Continue reading

JOANN Announces Participation in Shareholder Equity Conference

HUDSON, Ohio, March 21, 2022 (GLOBE NEWSWIRE) — JOANN Inc. (NASDAQ: JOAN) (“JOANN”), the nation’s category leader in sewing and one of the fastest growing competitors in the arts and crafts category, today announced that Wade Miquelon, President and CEO, and Matt Susz, CFO, will participate in the Shareholder Equity Conference, held virtually, on Monday, March 28, 2022 at 9:30AM ET. This conference is set in a fireside chat format and directed to provide access to retail investors. Investors will have the opportunity to ask management questions during the chat. The live stream of this presentation will be webcast live and can be accessed at https://share-conference-series.open-exchange.net/registration or in the “News and Events” section at https://investors.joann.com/. An archived replay will be available on the Shareholder Equity...

Continue reading

Atlas Technical Consultants Acquires 1 Alliance Geomatics

– Adds High-Tech Geomatics Capabilities in Key Transportation and Environmental Markets – AUSTIN, Texas, March 21, 2022 (GLOBE NEWSWIRE) — Atlas Technical Consultants, Inc. (Nasdaq: ATCX) (“Atlas” or the “Company”), a leading Infrastructure and Environmental solutions provider, announced today that it has acquired 1 Alliance Geomatics, LLC (“1 Alliance”), a provider of geospatial services to transportation and water resources markets in the Pacific Northwest. With over 70 employees, 1 Alliance utilizes the latest in geomatics technology, including 3D laser scanning and drones, to provide high quality and accurate data-driven solutions to its customers throughout the project lifecycle. “The acquisition of 1 Alliance adds another highly technical service to the Atlas portfolio that aligns with our goal to expand our service...

Continue reading

Condor Announces 2021 Year End Results

CALGARY, Alberta, March 21, 2022 (GLOBE NEWSWIRE) — Condor Petroleum Inc. (“Condor” or the “Company”) (TSX: CPI), a Canadian based oil and gas company focused on exploration and production activities in Turkey and Kazakhstan, is pleased to announce the release of its Consolidated Financial Statements for the year ended December 31, 2021, together with the related Management’s Discussion and Analysis. These documents will be made available under Condor’s profile on SEDAR at www.sedar.com and on the Condor website at www.condorpetroleum.com. Readers are invited to review the latest corporate presentation available on the Condor website. All financial amounts in this news release are presented in Canadian dollars, unless otherwise stated. HighlightsThe Company signed three Memorandum of Understandings (“MoUs”) with various Kazakhstan...

Continue reading

DICE Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

On track to deliver topline proof-of-concept data from Phase 1 clinical trial of oral IL-17 antagonist DC-806 in healthy volunteers and psoriasis patients in mid-2022 Named development candidate DC-853 from the novel scaffold program 1 series of oral IL-17 franchise Current cash provides runway through mid-2024 and multiple expected key clinical milestonesSOUTH SAN FRANCISCO, Calif., March 21, 2022 (GLOBE NEWSWIRE) — DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2021. “The past year has been a productive time for DICE and...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.